Eli Lilly

Know Labs Expands Board of Directors

Retrieved on: 
Wednesday, November 8, 2023

Tim Londergan is the founder and CEO of Tangibly, Inc., developer of the globe’s pre-eminent trade secret management platform. Trade secrets are a key component of an IP asset base and include the company’s proprietary algorithms. Londergan has a Ph.D. in Chemistry and experience as a CEO and COO of technology companies, including Lumera, Wavefront Venture Labs and Operem. He spent several years as Head of Commercial Development at Intellectual Ventures--a six-billion-dollar global intellectual property fund. In that role he managed a project between Intellectual Ventures and Know Labs to enhance Know Labs’ IP portfolio. Recently, Londergan was named IAM 300 World’s Leading IP Strategist 2023.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company’s Board of Directors.
  • Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs.
  • In that role he managed a project between Intellectual Ventures and Know Labs to enhance Know Labs’ IP portfolio.
  • We are thrilled to have John Cronin, Larry Ellingson and Tim Londergan join our Board of Directors.”
    For more information on Know Labs, visit www.knowlabs.co .

HARMONY BIOSCIENCES APPOINTS PETER ANASTASIOU TO ITS BOARD OF DIRECTORS

Retrieved on: 
Wednesday, November 8, 2023

PLYMOUTH MEETING, Pa., Nov. 8, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Peter Anastasiou to the Company's Board of Directors.

Key Points: 
  • PLYMOUTH MEETING, Pa., Nov. 8, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Peter Anastasiou to the Company's Board of Directors.
  • Anastasiou held various leadership positions at Lundbeck, where he was critical in shaping overall corporate strategy, R&D priorities, and business development.
  • "I am energized to join Harmony's Board of Directors at this critical stage of growth for the company.
  • "Peter's CNS and business development expertise will support Harmony's growth priorities," said Harmony Biosciences Chairman Jeff Aronin.

ProQR Announces Third Quarter 2023 Operating and Financial Results

Retrieved on: 
Tuesday, November 7, 2023

(Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today reported its financial and operating results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today reported its financial and operating results for the third quarter ended September 30, 2023, and provided a business update.
  • On September 30, 2023, ProQR held cash and cash equivalents of €120.6 million, compared to €94.8 million on December 31, 2022.
  • General and administrative costs were €3.3 million for the quarter ended September 30, 2023 compared to €5.4 million for the quarter ended September 30, 2022.
  • For further financial information for the period ending September 30, 2023, please refer to the financial statements appearing at the end of this release.

BioSpace Announces 2024 Best Places to Work in Biopharma Winners

Retrieved on: 
Tuesday, November 7, 2023

DES MOINES, Iowa, Nov. 7, 2023 /PRNewswire/ -- BioSpace, the leader in biopharma news and careers has published its 2024 Best Places to Work list.

Key Points: 
  • DES MOINES, Iowa, Nov. 7, 2023 /PRNewswire/ -- BioSpace, the leader in biopharma news and careers has published its 2024 Best Places to Work list.
  • The list includes 60 employers with U.S. operations that have been recognized as Best Places to Work by the life sciences community, with 30 ranked in large and small employer categories respectively.
  • "The high-level of interest we receive in Best Places to Work indicates that it is imperative employers look after their staff, culture and reputation for long-term success," said Josh Goodwin, BioSpace CEO.
  • To view the complete lists of 2024 Best Places to Work winners, click here .

Morimatsu International Adapts to the Changing World by Upholding Technological Innovation in Global Expansion

Retrieved on: 
Monday, November 6, 2023

Pioneering the internationalization of Chinese manufacturing companies, Morimatsu International Holdings Limited (HKEX: 2155.HK, hereinafter referred to as "Morimatsu International," "Morimatsu," or the "Company") has traversed over three decades.

Key Points: 
  • Pioneering the internationalization of Chinese manufacturing companies, Morimatsu International Holdings Limited (HKEX: 2155.HK, hereinafter referred to as "Morimatsu International," "Morimatsu," or the "Company") has traversed over three decades.
  • Today, Morimatsu has evolved into a multinational enterprise originating from the Asia-Pacific region, with a global presence and long-term partnerships with leading companies across various sectors.
  • What remains constant is their collaboration with Morimatsu, which embodies the spirit of innovation that keeps Morimatsu at the forefront of meeting customer needs.
  • Morimatsu International's global reach has helped it excel in different temporal and environmental contexts, ultimately becoming an international leader capable of rapidly adapting to changing demands in global markets.

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, November 2, 2023

as Chief Medical Officer, effective immediately.

Key Points: 
  • as Chief Medical Officer, effective immediately.
  • “I am pleased to welcome Dr. Strack to the vTv team,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics.
  • Most recently, he served as Chief Medical Officer of Faeth Therapeutics Inc., a clinical stage developer of metabolic oncology therapies.
  • He also served as Consultant in Medical Affairs at Omeros Corporation, a clinical stage biopharmaceutical company focused on small-molecule and protein therapeutics for immunologic disorders.

Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

Retrieved on: 
Wednesday, November 1, 2023

Bill Lis is stepping down as Chairperson and will retire from the Board in December of this year.

Key Points: 
  • Bill Lis is stepping down as Chairperson and will retire from the Board in December of this year.
  • “We are pleased to welcome Tom to our Board as Chairperson.
  • “I will be supporting Tom, Ron, and the rest of Jasper as I transition off the Jasper Board to new company ventures.”
    Mr. Wiggans most recently served as Chairman and CEO of Pardes Biosciences.
  • He began his career with Eli Lilly & Co. Mr. Wiggans is currently on the Board of Directors of Annexon, Inc., and Cymabay Therapeutics Inc.

China Pharmaceutical Competitive Landscape and Drugs Pipeline Analysis Report 2023: Business Overview of 330 Companies, 1500 Drugs in Trials, & 200 Commercially Approved Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, November 3, 2023

The "China Pharmaceutical Companies and Drugs Pipeline Insight 2023" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Pharmaceutical Companies and Drugs Pipeline Insight 2023" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • For as long as anybody can remember, the US has been the largest pharmaceutical market globally.
  • The Chinese pharmaceutical market is dynamic, with numerous unanticipated potential for future expansion, making it an ideal market to explore.
  • Chinese Pharmaceuticals Companies Business Overview Insight: 330 Companies
    Comprehensive Insight On Drugs In Clinical Trials By Companies: > 1500 Drugs
    Clinical Trials Insight By Companies, Indication, Formulation and Phase
    Comprehensive Insight On Drugs Commercially Approved In Market: > 200 Drugs

Rapport Therapeutics Appoints Chief Financial Officer

Retrieved on: 
Monday, October 30, 2023

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20231030359557/en/
    “We are thrilled to welcome Troy to the Rapport executive team during this time of rapid progress for our company,” said Abraham Ceesay, Chief Executive Officer of Rapport.
  • Most recently, he was Chief Financial Officer at Karuna Therapeutics, where he led the team in the execution of a private crossover round, the company’s IPO and multiple follow-on financings.
  • Prior to Karuna, Mr. Ignelzi served as Chief Financial Officer at two other companies, Juventas Therapeutics and scPharmaceuticals.

15th Annual SCOPE: Summit for Clinical Ops Executives Puts Spotlight on the Cell & Gene Therapies Supply Chain & Medical Device Trials, February 11-14, 2024, Orlando, FL

Retrieved on: 
Thursday, November 2, 2023

NEEDHAM, Mass., Nov. 2, 2023 /PRNewswire-PRWeb/ -- In response to the rapid expansion of the cell and gene therapy (CGT) market valued at $7.28 billion in 2022 and a predicted compound annual growth rate (CAGR) of 26.6% from 2023 to 2030 (as reported by MarketsandMarkets™), Cambridge Healthtech Institute (CHI) delves into the diverse clinical supply chain infrastructure designed for today's approved Cell and Gene Therapies (CGT), as well as supply strategies for those presently engaged in clinical trials, at its 15th annual SCOPE: Summit for Clinical Ops Executives, taking place February 11-14, 2024, in Orlando, FL, and online.

Key Points: 
  • The SCOPE Summit brings together over 3,300 executives and clinical operations experts.
  • All understand the necessity of making improvements to the clinical supply chain which is essential to meet the growing complexity of clinical trials, particularly in the context of rapidly evolving cell and gene therapies that are reshaping treatments and challenging established supply chain paradigms.
  • The summit will feature a dedicated stream on Clinical Supply, encompassing 2 distinct conferences: "Data Technology for End-to-End Clinical Supply Management" and "Clinical Supply Chain Strategies to Align Process, Products and Patients."
  • ( https://www.scopesummit.com/Clinical-Supply-Management )
    Furthermore, the event brings back its Medical Device Trials conferences focusing on trial design, operations, regulations, quality, and data management.